Search

Liz Davis

Co-director of Children’s Diabetes Centre

New funding targets diabetes and heart disease health service gaps

Researchers will work with Aboriginal & Torres Strait Islander women in SA to devise better ways to care for women at risk of pregnancy complications caused by diabetes and cardiovascular disease.

PhD pathway program ensuring bright future for clinical research in WA

Two outstanding Perth Children’s Hospital clinicians will be supported to pursue a career in medical research, paving the way for more clinician-scientists in Western Australia.

Five things that may surprise you about type 1 diabetes

Professor Liz Davis reveals five things you might not know about type 1 diabetes.

Promoting Resilience in Stress Management for Parents (PRISM-P) intervention in parents of young children with T1D

Keely Amy Tim Bebbington Finlay-Jones Jones MClinPsych/PhD BPsych(Hons), MPsych(Clinical), MHealthEcon, PhD (Clin Psych) MBBS DCH FRACP MD McCusker

Using co-design to understand and enhance the experiences of emerging adults with type 1 diabetes and their parents as they transition from paediatric to adult care in metropolitan and regional Western Australia

Keely Bebbington MClinPsych/PhD McCusker Postdoctoral Research Fellow in Type 1 Diabetes 08 6319 1766 keely.bebbington@thekids.org.au McCusker

Validation of Physical Activity Assessment in Type 1 Diabetes – an Essential Step to Incorporating Systematic Measurement of Activity as the Standard of Care in Youth

Liz Tim Davis Jones MBBS FRACP PhD MBBS DCH FRACP MD Co-director of Children’s Diabetes Centre Co-head, Diabetes and Obesity Research Co-director of

Short-Term Diabetic Retinopathy Status in People with Type 1 Diabetes Commencing Automated Insulin Delivery

Rapid improvements in glucose control may lead to early worsening of diabetic retinopathy (EWDR). There is a need to demonstrate safety in people commencing automated insulin delivery (AID) due to the known efficacy in rapid glycemic improvement. We aimed to investigate short-term DR outcomes in people (aged ≥13 years) with type 1 diabetes after initiation of AID (use ≥6 months).

X-Linked Hypophosphataemia and Burosumab: A Systemic Disease With a New Treatment

X linked hypophosphataemia (XLH) is a systemic, chronic condition that significantly impairs quality of life. In XLH, a phosphate regulating endopeptidase homologue X-linked (PHEX) gene mutation leads to excess fibroblast growth factor 23 (FGF23), causing hypophosphataemia and subsequent rickets, lower limb deformity, pain and other sequelae, however there are likely other non-FGF23 mediated mechanisms contributing to disease

Six months of hybrid closed-loop therapy improves diabetes-specific positive well-being, and reduces diabetes distress and fear of hypoglycemia: secondary analysis of a controlled trial

This analysis aimed to investigate diabetes-specific psychological outcomes among adults with type 1 diabetes (T1D) using hybrid closed-loop (HCL) versus standard therapy.